MicroRNA: A new therapeutic strategy for cardiovascular diseases

Trends in Cardiovascular Medicine

Volumn 26, Issue 5, 2016, Pages 407-419

  Samanta, Saheli ^a   Balasubramanian, Sathyamoorthy ^a,b   Rajasingh, Sheeja ^a   Patel, Urmi ^a   Dhanasekaran, Anuradha ^b   Dawn, Buddhadeb ^a   Rajasingh, Johnson ^a,c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b ANNA UNIVERSITY   (India)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiac fibrosis; Endothelial cells; Hypertension; MicroRNAs; Myocardial infarction; Stroke

Indexed keywords

CIRCULAR RNA; LONG UNTRANSLATED RNA; MICRORNA; PIWI INTERACTING RNA; SMALL CAJAL BODY SPECIFIC RNA; SMALL INTERFERING RNA; SMALL NUCLEOLAR RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA; GENETIC MARKER;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RNA SYNTHESIS; SMOOTH MUSCLE CELL; ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; GENE THERAPY; GENETIC MARKER; GENETICS; METABOLISM; MOLECULAR DIAGNOSIS; PREDICTIVE VALUE; PROCEDURES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; GENETIC MARKERS; GENETIC THERAPY; HUMANS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; PREDICTIVE VALUE OF TESTS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84961279178     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2016.02.004     Document Type: Review

References (104)

1. [1] Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., et al. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129 (2014), 399–410.
2. [2] Latronico, M.V., Catalucci, D., Condorelli, G., MicroRNA and cardiac pathologies. Physiol Genomics 34 (2008), 239–242.
3. [3] Claverie, J.M., Fewer genes, more noncoding RNA. Science 309 (2005), 1529–1530.
4. [4] van Rooij, E., Olson, E.N., MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 11 (2012), 860–872.
5. [5] Krol, J., Loedige, I., Filipowicz, W., The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11 (2010), 597–610.
6. [6] Cech, T.R., Steitz, J.A., The noncoding RNA revolution-trashing old rules to forge new ones. Cell 157 (2014), 77–94.
7. [7] Snead, N.M., Wu, X., Li, A., Cui, Q., Sakurai, K., Burnett, J.C., et al. Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants. Nucleic Acids Res 41 (2013), 6209–6221.
8. [8] Brennecke, J., Aravin, A.A., Stark, A., Dus, M., Kellis, M., Sachidanandam, R., et al. Discrete small RNA-generating loci as master regulators of transposon activity in drosophila. Cell 128 (2007), 1089–1103.
9. [9] King, T.H., Liu, B., McCully, R.R., Fournier, M.J., Ribosome structure and activity are altered in cells lacking snoRNPs that form pseudouridines in the peptidyl transferase center. Mol Cell 11 (2003), 425–435.
10. [10] Marz, M., Gruber, A.R., Honer Zu Siederdissen, C., Amman, F., Badelt, S., Bartschat, S., et al. Animal snoRNAs and scaRNAs with exceptional structures. RNA Biol 8 (2011), 938–946.
11. [11] Lara-Pezzi, E., Dopazo, A., Manzanares, M., Understanding cardiovascular disease: a journey through the genome (and what we found there). Dis Model Mech 5 (2012), 434–443.
12. [12] O'Brien, J.E. Jr, Kibiryeva, N., Zhou, X.G., Marshall, J.A., Lofland, G.K., Artman, M., et al. Noncoding RNA expression in myocardium from infants with tetralogy of Fallot. Circ Cardiovasc Genet 5 (2012), 279–286.
13. [13] Mercer, T.R., Dinger, M.E., Mattick, J.S., Long non-coding RNAs: insights into functions. Nat Rev Genet 10 (2009), 155–159.
14. [14] Uchida, S., Dimmeler, S., Long noncoding RNAs in cardiovascular diseases. Circ Res 116 (2015), 737–750.
15. [15] Guo, J.U., Agarwal, V., Guo, H., Bartel, D.P., Expanded identification and characterization of mammalian circular RNAs. Genome Biol, 15, 2014, 409.
16. [16] Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495 (2013), 333–338.
17. [17] Lee, R.C., Feinbaum, R.L., Ambros, V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75 (1993), 843–854.
18. [18] Cordes, K.R., Srivastava, D., Ivey, K.N., MicroRNAs in cardiac development. Pediatr Cardiol 31 (2010), 349–356.
19. [19] Vasudevan, S., Tong, Y., Steitz, J.A., Switching from repression to activation: microRNAs can up-regulate translation. Science 318 (2007), 1931–1934.
20. [20] Winter, J., Jung, S., Keller, S., Gregory, R.I., Diederichs, S., Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11 (2009), 228–234.
21. [21] Kim, V.N., Small RNAs: classification, biogenesis, and function. Mol Cells 19 (2005), 1–15.
22. [22] Han, J., Lee, Y., Yeom, K.H., Nam, J.W., Heo, I., Rhee, J.K., et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 125 (2006), 887–901.
23. [23] Kim, V.N., MicroRNA precursors in motion: exportin-5 mediates their nuclear export. Trends Cell Biol 14 (2004), 156–159.
24. [24] Hammond, S.M., Boettcher, S., Caudy, A.A., Kobayashi, R., Hannon, G.J., Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 293 (2001), 1146–1150.
25. [25] Boominathan, L., The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One, 5, 2010, e10615.
26. [26] Sucharov, C., Bristow, M.R., Port, J.D., miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 45 (2008), 185–192.
27. [27] Trang, P., Wiggins, J.F., Daige, C.L., Cho, C., Omotola, M., Brown, D., et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19 (2011), 1116–1122.
28. [28] Sayed, A.S., Xia, K., Salma, U., Yang, T., Peng, J., Diagnosis, prognosis and therapeutic role of circulating miRNAs in cardiovascular diseases. Heart Lung Circ 23 (2014), 503–510.
29. [29] Volny, O., Kasickova, L., Coufalova, D., Cimflova, P., Novak, J., microRNAs in Cerebrovascular Disease. Adv Exp Med Biol 888 (2015), 155–195.
30. [30] Libby, P., Ridker, P.M., Hansson, G.K., Progress and challenges in translating the biology of atherosclerosis. Nature 473 (2011), 317–325.
31. [31] Yamakuchi, M., MicroRNAs in Vascular Biology. Int J Vasc Med, 2012, 2012, 794898.
32. [32] Sun, X., Belkin, N., Feinberg, M.W., Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep, 15, 2013, 372.
33. [33] Staszel, T., Zapala, B., Polus, A., Sadakierska-Chudy, A., Kiec-Wilk, B., Stepien, E., et al. Role of microRNAs in endothelial cell pathophysiology. Pol Arch Med Wewn 121 (2011), 361–366.
34. [34] Guo, M., Mao, X., Ji, Q., Lang, M., Li, S., Peng, Y., et al. miR-146a in PBMCs modulates Th1 function in patients with acute coronary syndrome. Immunol Cell Biol 88 (2010), 555–564.
35. [35] Fang, Y., Shi, C., Manduchi, E., Civelek, M., Davies, P.F., MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A 107 (2010), 13450–13455.
36. [36] Schober, A., Nazari-Jahantigh, M., Wei, Y., Bidzhekov, K., Gremse, F., Grommes, J., et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 20 (2014), 368–376.
37. [37] Fish, J.E., Santoro, M.M., Morton, S.U., Yu, S., Yeh, R.F., Wythe, J.D., et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15 (2008), 272–284.
38. [38] Cheng, H.S., Sivachandran, N., Lau, A., Boudreau, E., Zhao, J.L., Baltimore, D., et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med 5 (2013), 949–966.
39. [39] Vickers, K.C., Landstreet, S.R., Levin, MG, Shoucri, B.M., Toth, C.L., Taylor, R.C., et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci U S A 111 (2014), 14518–14523.
40. [40] Zhang, Y., Qin, W., Zhang, L., Wu, X., Du, N., Hu, Y., et al. MicroRNA-26a prevents endothelial cell apoptosis by directly targeting TRPC6 in the setting of atherosclerosis. Sci Rep, 5, 2015, 9401.
41. [41] Liu, X., Cheng, Y., Zhang, S., Lin, Y., Yang, J., Zhang, C., A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 104 (2009), 476–487.
42. [42] Ji, R., Cheng, Y., Yue, J., Yang, J, Liu, X., Chen, H., et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 100 (2007), 1579–1588.
43. [43] Cordes, K.R., Sheehy, N.T., White, M.P., Berry, E.C., Morton, S.U., Muth, A.N., et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460 (2009), 705–710.
44. [44] Boettger, T., Beetz, N., Kostin, S., Schneider, J., Kruger, M., Hein, L., et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 119 (2009), 2634–2647.
45. [45] Bertero, T., Lu, Y., Annis, S., Hale, A., Bhat, B., Saggar, R., et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest 124 (2014), 3514–3528.
46. [46] Angelovich, T.A., Hearps, A.C., Jaworowski, A., Inflammation-induced foam cell formation in chronic inflammatory disease. Immunol Cell Biol 93 (2015), 683–693.
47. [47] Chang, R.C., Ying, W., Bazer, F.W., Zhou, B., MicroRNAs control macrophage formation and activation: the inflammatory link between obesity and cardiovascular diseases. Cells 3 (2014), 702–712.
48. [48] Nakamachi, Y., Kawano, S., Takenokuchi, M., Nishimura, K., Sakai, Y., Chin, T., et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 60 (2009), 1294–1304.
49. [49] Zhu, D, Pan, C, Li, L, Bian, Z, Lv, Z, Shi, L, et al. MicroRNA-17/20a/106a modulate macrophage inflammatory responses through targeting signal-regulatory protein alpha. J Allergy Clin Immunol, 132, 2013, e8.
50. [50] Lovren, F., Pan, Y., Quan, A., Singh, K.K., Shukla, P.C., Gupta, N., et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 126 (2012), S81–S90.
51. [51] Dorhoi, A., Iannaccone, M., Farinacci, M., Fae, K.C., Schreiber, J., Moura-Alves, P., et al. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest 123 (2013), 4836–4848.
52. [52] Wei, Y., Zhu, M., Corbalan-Campos, J., Heyll, K., Weber, C., Schober, A., Regulation of Csf1r and Bcl6 in macrophages mediates the stage-specific effects of microRNA-155 on atherosclerosis. Arterioscler Thromb Vasc Biol 35 (2015), 796–803.
53. [53] Wei, Y., Nazari-Jahantigh, M., Chan, L., Zhu, M., Heyll, K., Corbalan-Campos, J., et al. The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation 127 (2013), 1609–1619.
54. [54] Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R., Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
55. [55] Huang, J.B., Liang, J., Zhao, X.F., Wu, W.S., Zhang, F., Epigenetics: novel mechanism of pulmonary hypertension. Lung 191 (2013), 601–610.
56. [56] Parikh, V.N., Jin, R.C., Rabello, S., Gulbahce, N., White, K., Hale, A., et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 125 (2012), 1520–1532.
57. [57] Wang, D., Zhang, H., Li, M., Frid, M.G., Flockton, A.R., McKeon, B.A., et al. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res 114 (2014), 67–78.
58. [58] Sober, S., Laan, M., Annilo, T., MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression. Biochem Biophys Res Commun 391 (2010), 727–732.
59. [59] Sun, H.X., Zeng, D.Y., Li, R.T., Pang, R.P., Yang, H., Hu, Y.L., et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 60 (2012), 1407–1414.
60. [60] Ai, J., Zhang, R., Li, Y., Pu, J., Lu, Y., Jiao, J., et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 391 (2010), 73–77.
61. [61] D'Alessandra, Y., Devanna, P., Limana, F., Straino, S., Di Carlo, A., Brambilla, P.G., et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 31 (2010), 2765–2773.
62. [62] Yin, C., Salloum, F.N., Kukreja, R.C., A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70. Circ Res 104 (2009), 572–575.
63. [63] Ren, X.P., Wu, J., Wang, X., Sartor, M.A., Qian, J., Jones, K., et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 119 (2009), 2357–2366.
64. [64] Roy, S., Khanna, S., Hussain, S.R., Biswas, S., Azad, A., Rink, C., et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 82 (2009), 21–29.
65. [65] Izarra, A., Moscoso, I., Levent, E., Canon, S., Cerrada, I., Diez-Juan, A., et al. miR-133a enhances the protective capacity of cardiac progenitors cells after myocardial infarction. Stem Cell Reports 3 (2014), 1029–1042.
66. [66] Wang, J., Huang, W., Xu, R., Nie, Y., Cao, X., Meng, J., et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 16 (2012), 2150–2160.
67. [67] Icli, B., Dorbala, P., Feinberg, M.W., An emerging role for the miR-26 family in cardiovascular disease. Trends Cardiovasc Med 24 (2014), 241–248.
68. [68] van Rooij, E., Sutherland, L.B., Thatcher, J.E., DiMaio, J.M., Naseem, R.H., Marshall, W.S., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105 (2008), 13027–13032.
69. [69] Park, S.Y., Lee, J.H., Ha, M., Nam, J.W., Kim, V.N., miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 16 (2009), 23–29.
70. [70] Li, S.P., Liu, B., Song, B., Wang, C.X., Zhou, Y.C., miR-28 promotes cardiac ischemia by targeting mitochondrial aldehyde dehydrogenase 2 (ALDH2) in Mus musculus cardiac myocytes. Eur Rev Med Pharmacol Sci 19 (2015), 752–758.
71. [71] Joladarashi, D., Srikanth Garikipati, V.N., Thandavarayan, R.A., Verma, S.K., Mackie, AR, Khan, M., et al. Enhanced cardiac regenerative ability of stem cells after ischemia-reperfusion injury: role of human CD34(+) cells deficient in MicroRNA-377. J Am Coll Cardiol 66 (2015), 2214–2226.
72. [72] Force, T., Bonow, R.O., Houser, S.R., Solaro, R.J., Hershberger, R.E., Adhikari, B., et al. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation 122 (2010), 1130–1133.
73. [73] Levy, D., Garrison, R.J., Savage, D.D., Kannel, W.B., Castelli, W.P., Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990), 1561–1566.
74. [74] Da Costa Martins, P.A., De Windt, L.J., MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res 93 (2012), 563–572.
75. [75] Joladarashi, D., Thandavarayan, R.A., Babu, S.S., Krishnamurthy, P., Small engine, big power: microRNAs as regulators of cardiac diseases and regeneration. Int J Mol Sci 15 (2014), 15891–15911.
76. [76] Devaux, Y., Stammet, P., Friberg, H., Hassager, C., Kuiper, M.A., Wise, M.P., et al. MicroRNAs: new biomarkers and therapeutic targets after cardiac arrest?. Crit Care, 19, 2015, 767.
77. [77] Nagalingam, R.S., Sundaresan, N.R., Noor, M., Gupta, M.P., Solaro, R.J., Gupta, M., Deficiency of cardiomyocyte-specific microRNA-378 contributes to the development of cardiac fibrosis involving a transforming growth factor beta (TGFbeta1)-dependent paracrine mechanism. J Biol Chem 289 (2014), 27199–27214.
78. [78] Care, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 13 (2007), 613–618.
79. [79] Ikeda, S., He, A., Kong, S.W., Lu, J., Bejar, R., Bodyak, N., et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 29 (2009), 2193–2204.
80. [80] Bernardo, B.C., Nguyen, S.S., Winbanks, C.E., Gao, X.M., Boey, E.J., Tham, Y.K., et al. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J 28 (2014), 5097–5110.
81. [81] Wang, Y.S., Zhou, J., Hong, K., Cheng, X.S., Li, Y.G., MicroRNA-223 displays a protective role against cardiomyocyte hypertrophy by targeting cardiac troponin I-interacting kinase. Cell Physiol Biochem 35 (2015), 1546–1556.
82. [82] Ucar, A., Gupta, S.K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun, 3, 2012, 1078.
83. [83] Tao, H., Shi, K.H., Yang, J.J., Huang, C., Liu, L.P., Li, J., Epigenetic regulation of cardiac fibrosis. Cell Signal 25 (2013), 1932–1938.
84. [84] Meiners, S., Hocher, B., Weller, A., Laule, M., Stangl, V., Guenther, C., et al. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension 44 (2004), 471–477.
85. [85] He, Y., Huang, C., Lin, X., Li, J., MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie 95 (2013), 1355–1359.
86. [86] Li, R., Xiao, J., Qing, X., Xing, J., Xia, Y., Qi, J., et al. Sp1 mediates a therapeutic role of MiR-7a/b in angiotensin ii-induced cardiac fibrosis via mechanism involving the TGF-beta and MAPKs pathways in cardiac fibroblasts. PLoS One, 10, 2015, e0125513.
87. [87] Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456 (2008), 980–984.
88. [88] Dong, S., Ma, W., Hao, B., Hu, F., Yan, L., Yan, X., et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol 7 (2014), 565–574.
89. [89] Duisters, R.F., Tijsen, A.J., Schroen, B., Leenders, J.J., Lentink, V., van der Made, I., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res, 104, 2009 [6p following 8].
90. [90] Beaumont, J., Lopez, B., Hermida, N., Schroen, B., San Jose, G., Heymans, S., et al. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-beta1 up-regulation. Clin Sci (Lond) 126 (2014), 497–506.
91. [91] Tijsen, A.J., van der Made, I., van den Hoogenhof, M.M., Wijnen, W.J., van Deel, E.D., de Groot, N.E., et al. The microRNA-15 family inhibits the TGFbeta-pathway in the heart. Cardiovasc Res 104 (2014), 61–71.
92. [92] Kishore, R., Verma, S.K., Mackie, A.R., Vaughan, E.E., Abramova, T.V., Aiko, I., et al. Bone marrow progenitor cell therapy-mediated paracrine regulation of cardiac miRNA-155 modulates fibrotic response in diabetic hearts. PLoS One, 8, 2013, e60161.
93. [93] Zhou, Y, Deng, L, Zhao, D, Chen, L, Yao, Z, Guo, X, et al. MicroRNA-503 promotes angiotensin II-induced cardiac fibrosis by targeting Apelin-13. J Cell Mol Med, 2016.
94. [94] Tan, K.S., Armugam, A., Sepramaniam, S., Lim, K.Y., Setyowati, K.D., Wang, C.W., et al. Expression profile of MicroRNAs in young stroke patients. PLoS One, 4, 2009, e7689.
95. [95] Pandi, G., Nakka, V.P., Dharap, A., Roopra, A., Vemuganti, R., MicroRNA miR-29c down-regulation leading to de-repression of its target DNA methyltransferase 3a promotes ischemic brain damage. PLoS One, 8, 2013, e58039.
96. [96] Yin, K.J., Deng, Z., Huang, H., Hamblin, M., Xie, C., Zhang, J., et al. miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia. Neurobiol Dis 38 (2010), 17–26.
97. [97] Sempere, L.F., Freemantle, S., Pitha-Rowe, I., Moss, E., Dmitrovsky, E., Ambros, V., Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol, 5, 2004, R13.
98. [98] Dhiraj, D.K., Chrysanthou, E., Mallucci, G.R., Bushell, M., miRNAs-19b, -29b-2* and -339-5p show an early and sustained up-regulation in ischemic models of stroke. PLoS One, 8, 2013, e83717.
99. [99] Faruq, O., Vecchione, A., microRNA: diagnostic perspective. Front Med (Lausanne), 2, 2015, 51.
100. [100] Tijsen, A.J., Creemers, E.E., Moerland, P.D., de Windt, L.J., van der Wal, A.C., Kok, W.E., et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 106 (2010), 1035–1039.
101. [101] Fan, K.L., Zhang, H.F., Shen, J., Zhang, Q., Li, X.L., Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J 65 (2013), 12–16.
102. [102] Fichtlscherer, S., De Rosa, S., Fox, H., Schwietz, T., Fischer, A., Liebetrau, C., et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 107 (2010), 677–684.
103. [103] Bostjancic, E., Zidar, N., Stajer, D., Glavac, D., MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 115 (2010), 163–169.
104. [104] Cho, W.C.S., MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 42 (2010), 1273–1281.